| 0539T |
CAR-T THERAPY RECEIPT & PREP CAR-T CELLS F/ADMN |
|
| 86359 |
T CELLS TOTAL |
|
| 86360 |
T CELLS CD4 8 RATIO |
|
| 86361 |
T CELLS CD4 COUNT |
|
| 38204 |
TC THERAPEUTIC CELL (T-CELLS), HEMATOPOIETIC PROGENITOR |
|
| 581 |
Lab/T Cells |
|
| 86359 |
T cells; total count |
|
| 86359 |
T CELLS TOTAL COUNT |
T cells count, total |
| 86359 |
HC T CELLS TOTAL COUNT |
|
| 86359 |
T-CELLS TOTAL COUNT |
|
| 86359 |
FLOW CYTOMETRY T CELLS TOTAL COUNT |
|
| 86359 |
CD3 -T CELLS |
|
| 86359 |
T Cells Total Count SO |
|
| 86360 |
T cells; absolute CD4 and CD8 count, including ratio |
|
| 86360 |
T CELLS INCLUDING RATIO |
|
| 86360 |
HC T CELLS INCLUDING RATIO |
|
| 86361 |
T cells; absolute CD4 count |
|
| 86361 |
T Cells Absolute Cd4 SO |
|
| 86481 |
Tuberculosis test, cell mediated immunity antigen response measurement; enumeration of gamma interferon-producing T-cells in cell suspension |
Tb Test, Quantiferon |
| 88184 |
%CD4+CD45RO+ MEMORY T CELLS-MAYO |
|
| Q2040 |
TISAGENLECLEUCEL TO 250 M CAR-POS VI T CELLS-INF |
|
| Q2041 |
Axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose |
AXICABTAGENE CILOLEUCEL INTRAVENOUS SUSPENSION |
| Q2042 |
Tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose |
TISAGENLECLEUCEL 0.2 X10EXP6 TO 2.5X10EXP8 CELL INTRAVENOUS SUSPENSION |
| Q2053 |
Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose |
|
| Q2054 |
Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose |
|
| Q2056 |
Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose |
|
| Q2055 |
Idecabtagene vicleucel, up to 510 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose |
|
| C9081 |
Idecabtagene vicleucel, up to 460 million autologous anti-bcma car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose |
|